FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023504042> ?p ?o ?g. }

• W2023504042 endingPage "623" @default.
• W2023504042 startingPage "613" @default.
• W2023504042 abstract "Adenosine A(2A) receptor antagonists have emerged as an attractive non-dopaminergic target in clinical trials aimed at evaluating improvement in motor deficits in Parkinson's disease (PD). Moreover, preclinical studies suggest that A(2A) receptor antagonists may slow the course of the underlying neurodegeneration of dopaminergic neurons. In this study, we evaluated the efficacy of the new adenosine A(2A) receptor antagonist 8-ethoxy-9-ethyladenine (ANR 94) in parkinsonian models of akinesia and tremor. In addition, induction of the immediate early gene zif-268, and neuroprotective and anti-inflammatory effects of ANR 94 were evaluated. ANR 94 was effective in reversing parkinsonian tremor induced by the administration of tacrine. ANR 94 also counteracted akinesia (stepping test) and sensorimotor deficits (vibrissae-elicited forelimb-placing test), as well as potentiating l-dopa-induced contralateral turning behavior in 6-hydroxydopamine (6-OHDA) lesion model of PD. Potentiation of motor behavior in 6-OHDA-lesioned rats was not associated with increased induction of the immediate early gene zif-268 in the striatum, suggesting that ANR 94 does not induce long-term plastic changes in this structure. Finally, in a subchronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, ANR 94 protected nigrostriatal dopaminergic neurons from degeneration and counteracted neuroinflammatory processes by contrasting astroglial (glial fibrillary acidic protein, GFAP) and microglial (CD11b) activation. A(2A) receptor antagonism represents a uniquely realistic opportunity for improving PD treatment, since A(2A) receptor antagonists offer substantial symptomatic benefits and possibly disease-modifying activity. The characterization of ANR 94 may represent a further therapeutic opportunity for the treatment of PD with this new class of drugs." @default.
• W2023504042 created "2016-06-24" @default.
• W2023504042 creator A5009432809 @default.
• W2023504042 creator A5017920493 @default.
• W2023504042 creator A5037805233 @default.
• W2023504042 creator A5045993408 @default.
• W2023504042 creator A5061603789 @default.
• W2023504042 creator A5062354189 @default.
• W2023504042 creator A5067548428 @default.
• W2023504042 creator A5085458129 @default.
• W2023504042 date "2010-03-01" @default.
• W2023504042 modified "2023-10-09" @default.
• W2023504042 title "A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug" @default.
• W2023504042 cites W1755157204 @default.
• W2023504042 cites W1969782593 @default.
• W2023504042 cites W1974384906 @default.
• W2023504042 cites W1982703610 @default.
• W2023504042 cites W1986087013 @default.
• W2023504042 cites W1987023203 @default.
• W2023504042 cites W1987380827 @default.
• W2023504042 cites W1990269363 @default.
• W2023504042 cites W2010405290 @default.
• W2023504042 cites W2010916577 @default.
• W2023504042 cites W2017686520 @default.
• W2023504042 cites W2019511637 @default.
• W2023504042 cites W2021419663 @default.
• W2023504042 cites W2025284540 @default.
• W2023504042 cites W2026475932 @default.
• W2023504042 cites W2029274732 @default.
• W2023504042 cites W2030108063 @default.
• W2023504042 cites W2032605993 @default.
• W2023504042 cites W2033564079 @default.
• W2023504042 cites W2034588648 @default.
• W2023504042 cites W2037199903 @default.
• W2023504042 cites W2038636807 @default.
• W2023504042 cites W2040527962 @default.
• W2023504042 cites W2043304533 @default.
• W2023504042 cites W2045678127 @default.
• W2023504042 cites W2046736001 @default.
• W2023504042 cites W2048424139 @default.
• W2023504042 cites W2056890984 @default.
• W2023504042 cites W2071443230 @default.
• W2023504042 cites W2078747341 @default.
• W2023504042 cites W2083496399 @default.
• W2023504042 cites W2096692295 @default.
• W2023504042 cites W2105882492 @default.
• W2023504042 cites W2109593203 @default.
• W2023504042 cites W2111597060 @default.
• W2023504042 cites W2115736681 @default.
• W2023504042 cites W2120634420 @default.
• W2023504042 cites W2120812632 @default.
• W2023504042 cites W2130570136 @default.
• W2023504042 cites W2136254234 @default.
• W2023504042 cites W2138535275 @default.
• W2023504042 cites W2145529172 @default.
• W2023504042 cites W2148726772 @default.
• W2023504042 cites W2150792183 @default.
• W2023504042 cites W2164457608 @default.
• W2023504042 cites W2166496419 @default.
• W2023504042 cites W4296025734 @default.
• W2023504042 doi "https://doi.org/10.1016/j.neuropharm.2009.11.012" @default.
• W2023504042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19951715" @default.
• W2023504042 hasPublicationYear "2010" @default.
• W2023504042 type Work @default.
• W2023504042 sameAs 2023504042 @default.
• W2023504042 citedByCount "44" @default.
• W2023504042 countsByYear W20235040422012 @default.
• W2023504042 countsByYear W20235040422013 @default.
• W2023504042 countsByYear W20235040422014 @default.
• W2023504042 countsByYear W20235040422015 @default.
• W2023504042 countsByYear W20235040422016 @default.
• W2023504042 countsByYear W20235040422017 @default.
• W2023504042 countsByYear W20235040422018 @default.
• W2023504042 countsByYear W20235040422019 @default.
• W2023504042 countsByYear W20235040422021 @default.
• W2023504042 countsByYear W20235040422022 @default.
• W2023504042 countsByYear W20235040422023 @default.
• W2023504042 crossrefType "journal-article" @default.
• W2023504042 hasAuthorship W2023504042A5009432809 @default.
• W2023504042 hasAuthorship W2023504042A5017920493 @default.
• W2023504042 hasAuthorship W2023504042A5037805233 @default.
• W2023504042 hasAuthorship W2023504042A5045993408 @default.
• W2023504042 hasAuthorship W2023504042A5061603789 @default.
• W2023504042 hasAuthorship W2023504042A5062354189 @default.
• W2023504042 hasAuthorship W2023504042A5067548428 @default.
• W2023504042 hasAuthorship W2023504042A5085458129 @default.
• W2023504042 hasConcept C126322002 @default.
• W2023504042 hasConcept C137183658 @default.
• W2023504042 hasConcept C169760540 @default.
• W2023504042 hasConcept C170493617 @default.
• W2023504042 hasConcept C25498285 @default.
• W2023504042 hasConcept C2776925932 @default.
• W2023504042 hasConcept C2778491162 @default.
• W2023504042 hasConcept C2778938600 @default.
• W2023504042 hasConcept C2779134260 @default.
• W2023504042 hasConcept C2780062018 @default.
• W2023504042 hasConcept C513476851 @default.
• W2023504042 hasConcept C67907053 @default.

• next